<DOC>
	<DOCNO>NCT01505400</DOCNO>
	<brief_summary>Substantial progress make treatment cancer use target therapy , work one patient might work another patient . Certain drug develop target specific molecule body believe part disease . Biomarkers specific characteristic cancer may help provide prognostic information ( i.e . well patient regardless treatment give ) help predict sensitivity resistance specific treatment . The study collect archival tumor sample ( previously collect biopsy surgical tumor sample ) provide biomarker data patient 's cancer , order help physician identify clinical trial molecularly target therapy may appropriate patient future .</brief_summary>
	<brief_title>Integrated Molecular Profiling Advanced Cancers Trial</brief_title>
	<detailed_description>The increase appreciation identification specific somatic mutation genetic aberration drive cancer leave u threshold new era `` personalized cancer medicine '' , specific biomarkers use direct targeted agent patient deem likely respond . The potential medical , scientific economic benefit personalize approach cancer therapy immense self-evident . Yet despite important advance , limited number approve targeted agent approval predicate specific biomarkers sensitivity resistance . The premise behind personalized cancer medicine include : ) genetic aberration exist human malignancy ; ii ) subset aberration , often present across multiple cancer type , functional relevance `` hallmark '' `` driver '' oncogenesis tumor progression ; iii ) genetic aberration potentially `` druggable '' target ; iv ) tolerable medicinal compound effectively modulate target . A key requirement new , personalized approach anti-cancer therapy specific patient must match particular drug combination drug . Molecular profiling tumor identify somatic mutation and/or genetic aberration examples enrichment strategy assist match patient drug treatment gain increase interest oncology community . The present protocol seek provide molecular profile data treat physician patient advance breast , non-small cell lung , colorectal , genitourinary , pancreatobiliary gastrointestinal , upper aerodigestive tract , gynecological , melanoma , unknown primary , rare carcinoma , well patient phase I trial candidate , order help identify standard regimen clinical trial molecularly target therapy may appropriate individual patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<criteria>Patients histological confirmation advance breast , nonsmall cell lung , colorectal , genitourinary , pancreatobiliary gastrointestinal , upper aerodigestive tract , gynecological , melanoma , unknown primary , rare carcinoma candidate systemic therapy , well patient phase I trial candidate . Patient must â‰¥ 18 year old . Patient 's ECOG performance status equal 0 1 . All patient must sign date informed consent form . All patient must sufficient archived tumor tissue molecular profiling .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Molecular profiling</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Genitourinary cancer</keyword>
	<keyword>Pancreatobiliary gastrointestinal cancer</keyword>
	<keyword>Upper aerodigestive tract cancer</keyword>
	<keyword>Gynecological cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase I Clinical Trial Candidates</keyword>
	<keyword>melanoma cancer</keyword>
	<keyword>rare cancer</keyword>
	<keyword>unknown primary cancer</keyword>
</DOC>